^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK rearrangement + KRAS mutation

    i
    Other names: Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Comprehensive analysis of mutational profile and prognostic significance of complex glandular pattern in lung adenocarcinoma. (PubMed, Transl Lung Cancer Res)
    There was also no significant difference in RFS and OS between the 20-49% and ≥50% group. Our study provided mutational profile of patients with different CGP, validated CGP as a negative prognostic factor and provided extra evidences for the optimal cut-off value of CGP percentage.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • ALK rearrangement + KRAS mutation
    4years
    [VIRTUAL] The Molecular Genomic Profiling of Primary Lung Adenocarcinoma in Local Population (CAP 2020)
    In these patients with lung adenocarcinoma, actionable variants in TP53, KRAS, NF1, EGFR, STK11, CDK4,and CDKN2 were more commonly identified, and in PIK3CA to a lesser extent. KRAS and NF1 are key components of the RAS-MAPK signaling pathway. The mutation-induced KRAS amplification or NF1 down-regulation leading to RAS-MAPK pathway hyperactivation may be related to rapid disease progression or induce resistance to conventional treatment.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDK4 (Cyclin-dependent kinase 4) • SMAD4 (SMAD family member 4)
    |
    KRAS mutation • EGFR mutation • KRAS G12D • ALK rearrangement • NF1 mutation • KRAS G12 • EGFR mutation + KRAS mutation • ALK rearrangement + KRAS mutation
    |
    Mekinist (trametinib)